DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival

J. K. Wiencke (), Annette M. Molinaro, Gayathri Warrier, Terri Rice, Jennifer Clarke, Jennie W. Taylor, Margaret Wrensch, Helen Hansen, Lucie McCoy, Emily Tang, Stan J. Tamaki, Courtney M. Tamaki, Emily Nissen, Paige Bracci, Lucas A. Salas, Devin C. Koestler, Brock C. Christensen, Ze Zhang and Karl T. Kelsey
Additional contact information
J. K. Wiencke: University of California San Francisco
Annette M. Molinaro: University of California San Francisco
Gayathri Warrier: University of California San Francisco
Terri Rice: University of California San Francisco
Jennifer Clarke: University of California San Francisco
Jennie W. Taylor: University of California San Francisco
Margaret Wrensch: University of California San Francisco
Helen Hansen: University of California San Francisco
Lucie McCoy: University of California San Francisco
Emily Tang: University of California San Francisco
Stan J. Tamaki: University of California San Francisco
Courtney M. Tamaki: University of California San Francisco
Emily Nissen: University of Kansas Medical Center
Paige Bracci: University of California San Francisco
Lucas A. Salas: Dartmouth College
Devin C. Koestler: University of Kansas Medical Center
Brock C. Christensen: Dartmouth College
Ze Zhang: Dartmouth College
Karl T. Kelsey: Brown University

Nature Communications, 2022, vol. 13, issue 1, 1-16

Abstract: Abstract Assessing individual responses to glucocorticoid drug therapies that compromise immune status and affect survival outcomes in neuro-oncology is a great challenge. Here we introduce a blood-based neutrophil dexamethasone methylation index (NDMI) that provides a measure of the epigenetic response of subjects to dexamethasone. This marker outperforms conventional approaches based on leukocyte composition as a marker of glucocorticoid response. The NDMI is associated with low CD4 T cells and the accumulation of monocytic myeloid-derived suppressor cells and also serves as prognostic factor in glioma survival. In a non-glioma population, the NDMI increases with a history of prednisone use. Therefore, it may also be informative in other conditions where glucocorticoids are employed. We conclude that DNA methylation remodeling within the peripheral immune compartment is a rich source of clinically relevant markers of glucocorticoid response.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33215-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33215-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33215-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().